Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Up 648.8% in December

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) was the target of a large increase in short interest in December. As of December 15th, there was short interest totaling 98,252 shares, an increase of 648.8% from the November 30th total of 13,122 shares. Approximately 5.9% of the company’s stock are sold short. Based on an average daily volume of 108,651 shares, the short-interest ratio is presently 0.9 days. Based on an average daily volume of 108,651 shares, the short-interest ratio is presently 0.9 days. Approximately 5.9% of the company’s stock are sold short.

Acurx Pharmaceuticals Trading Down 2.2%

ACXP traded down $0.08 on Wednesday, hitting $3.42. 11,914 shares of the company’s stock traded hands, compared to its average volume of 246,619. The company’s 50 day simple moving average is $4.72 and its 200-day simple moving average is $6.03. Acurx Pharmaceuticals has a one year low of $3.17 and a one year high of $25.00. The firm has a market cap of $7.16 million, a price-to-earnings ratio of -0.40 and a beta of -1.25.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($1.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.38. As a group, equities analysts anticipate that Acurx Pharmaceuticals will post -0.89 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ACXP has been the subject of several analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $31.00 price objective on shares of Acurx Pharmaceuticals in a research note on Tuesday, September 30th. Finally, Wall Street Zen lowered shares of Acurx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $31.00.

Institutional Trading of Acurx Pharmaceuticals

An institutional investor recently bought a new position in Acurx Pharmaceuticals stock. Armistice Capital LLC purchased a new position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,078,540 shares of the company’s stock, valued at approximately $551,000. Armistice Capital LLC owned about 70.13% of Acurx Pharmaceuticals as of its most recent SEC filing. Institutional investors own 11.53% of the company’s stock.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).